(Q37781803)

23 August 2017

title

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results (English)

1 reference

23 August 2017

0 references

anti-retroviral agent

0 references

3

Christine Katlama

0 references

Robert L. Murphy

object named as

Robert L Murphy

series ordinal

2

0 references

Babafemi Taiwo

series ordinal

1

object named as

Babafemi Taiwo

1 reference

23 August 2017

language of work or name

1 reference

1 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

70

1 reference

23 August 2017

issue

13

1 reference

23 August 2017

page(s)

1629-1642

1 reference

https://scigraph.springernature.com/pub.10.2165/11538020-000000000-00000

23 August 2017

exact match

0 references

cites work

CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11538020-000000000-00000

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

21 January 2018

1 reference

12 December 2020

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

12 December 2020

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

1 reference

12 December 2020

Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants

1 reference

12 December 2020

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

1 reference

12 December 2020

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals

1 reference

12 December 2020

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

1 reference

12 December 2020

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227

1 reference

12 December 2020

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

1 reference

12 December 2020

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

1 reference

12 December 2020

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

1 reference

12 December 2020

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V

1 reference

12 December 2020

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

12 December 2020

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America

1 reference

12 December 2020

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials

1 reference

12 December 2020

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects

1 reference

12 December 2020

Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?

1 reference

12 December 2020

Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression

1 reference

12 December 2020

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

1 reference

12 December 2020

HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia.

1 reference

12 December 2020

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

1 reference

12 December 2020

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

1 reference

12 December 2020

Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme

1 reference

12 December 2020

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

1 reference

12 December 2020

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

12 December 2020

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

12 December 2020

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

1 reference

12 December 2020

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

12 December 2020

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

1 reference

12 December 2020

Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors

1 reference

12 December 2020

Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment

1 reference

12 December 2020

Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.

1 reference

12 December 2020

The prevalence of antiretroviral drug resistance in the United States

1 reference

12 December 2020

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

12 December 2020

Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus

1 reference

12 December 2020

Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants

1 reference

12 December 2020

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

12 December 2020

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

1 reference

12 December 2020

Investigational agents for salvage

1 reference

12 December 2020

High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor

1 reference

12 December 2020

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

1 reference

12 December 2020

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial

1 reference

12 December 2020

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

1 reference

12 December 2020

Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.

1 reference

12 December 2020

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

1 reference

12 December 2020

Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.

1 reference

12 December 2020

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

1 reference

12 December 2020

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

1 reference

12 December 2020

Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience

1 reference

12 December 2020

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

1 reference

12 December 2020

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression

1 reference

12 December 2020

Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in São Paulo City, Brazil

1 reference

12 December 2020

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

1 reference

12 December 2020

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject

1 reference

12 December 2020

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

1 reference

12 December 2020

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211

1 reference

12 December 2020

Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

1 reference

12 December 2020

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

1 reference

12 December 2020

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

1 reference

12 December 2020

High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.

1 reference

12 December 2020

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

1 reference

12 December 2020

Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients

1 reference

12 December 2020

Combination therapy with zidovudine, didanosine and saquinavir

1 reference

12 December 2020

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

1 reference

12 December 2020

High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings

1 reference

12 December 2020

Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery.

1 reference

12 December 2020

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier

1 reference

12 December 2020

Effect of early versus deferred antiretroviral therapy for HIV on survival

1 reference

12 December 2020

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir

1 reference

12 December 2020

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

1 reference

12 December 2020

Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil

1 reference

12 December 2020

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

1 reference

12 December 2020

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection

1 reference

12 December 2020

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

12 December 2020

Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial

1 reference

12 December 2020

Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir

1 reference

12 December 2020

Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection

1 reference

12 December 2020

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

12 December 2020

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

12 December 2020

Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients

1 reference

12 December 2020

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

1 reference

12 December 2020

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

1 reference

12 December 2020

Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1.

1 reference

12 December 2020

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

1 reference

12 December 2020

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates

1 reference

12 December 2020

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

1 reference

12 December 2020

10.2165/11538020-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1005104177

0 references

1 reference